首页> 外文期刊>AIDS Research and Therapy >Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia
【24h】

Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia

机译:埃塞俄比亚亚的斯亚贝巴有和没有结核病(TB)和潜在结核病感染(LTBI)的人类免疫缺陷病毒(HIV)-1感染患者中HAART的病毒学和免疫学结果

获取原文
       

摘要

Background HIV/TB coinfection remains a major challenge even after the initiation of HAART. Little is known about Mycobacterium tuberculosis (Mtb) specific immune restoration in relation to immunologic and virologic outcomes after long-term HAART during co-infections with latent and active TB. Methods A total of 232 adults, including 59 HIV patients with clinical TB (HIV?+?TB+), 125 HIV patients without clinical TB (HIV?+?TB-), 13 HIV negative active TB patients (HIV-TB+), and 10 HIV negative Tuberculin Skin TST positive (HIV-TST+), and 25 HIV-TST- individuals were recruited. HAART was initiated in 113 HIV?+?patients (28?TB?+?and 85?TB-), and anti-TB treatment for all TB cases. CD4+ T-cell count, HIV RNA load, and IFN-γ responses to ESAT-6/CFP-10 were measured at baseline, 6?months (M6), 18?months (M18) and 24?months (M24) after HAART initiation. Results The majority of HIV?+?TB- (70%, 81%, 84%) as well as HIV?+?TB?+?patients (60%, 77%, 80%) had virologic success (HIV RNA?Mtb specific IFN-γ response at baseline was significantly lower in HIV?+?TB?+?(3.6?pg/ml) compared to HIV-TB?+?patients (34.4?pg/ml) and HIV?+?TST?+?(46.3?pg/ml) individuals; and in HIV-TB?+?patients compared to HIV-TST?+?individuals (491.2?pg/ml). By M18 on HAART, the IFN-γ response remained impaired in HIV?+?TB?+?patients (18.1?pg/ml) while it normalized in HIV?+?TST?+?individuals (from 46.3 to 414.2?pg/ml). Conclusions Our data show that clinical and latent TB infections do not influence virologic and immunologic outcomes of ART in HIV patients. Despite this, HAART was unable to restore optimal TB responsiveness as measured by Mtb specific IFN-γ response in HIV/TB patients. Improvement of Mtb-specific immune restoration should be the focus of future therapeutic strategies.
机译:背景技术即使在启动HAART之后,HIV / TB合并感染仍然是一个重大挑战。关于在潜在和活动性TB合并感染期间长期HAART后长期的HAART后与结核分枝杆菌(Mtb)特异性免疫修复有关的免疫学和病毒学结果知之甚少。方法共有232名成人,包括59例临床结核病(HIV?+?TB +)的HIV患者,125例无临床结核病的HIV(HIV?+?TB-),13例HIV阴性活动性结核病患者(HIV-TB +),以及招募了10例HIV阴性结核菌素皮肤TST阳性(HIV-TST +)和25例HIV-TST-个体。 HAART已在113名HIV +病人(28 TB +和85 TB-)中启动,并对所有结核病例进行了抗结核治疗。在基线,HAART后6个月(M6),18个月(M18)和24个月(M24)时测量CD4 + T细胞计数,HIV RNA载量和对ESAT-6 / CFP-10的IFN-γ反应引发。结果大部分HIV + + TB-(70%,81%,84%)以及HIV + +TBβ+-患者(60%,77%,80%)均获得病毒学成功(HIV RNA?Mtb)与HIV-TBα+β患者(34.4μpg/ ml)和HIVβ+βTSTβ+相比,HIVα+βTBα+β(3.6μpg/ ml)基线时的特异性IFN-γ反应显着降低。 ?(46.3?pg / ml)个体;与HIV-TST?+?个人(491.2?pg / ml)相比,在HIV-TB?+?患者中,通过HAART的M18,HIV中的IFN-γ反应仍然受损?+?TB?+?患者(18.1?pg / ml)在HIV?+?TST?+?个人(从46.3至414.2?pg / ml)中恢复正常时结论结论我们的数据表明临床和潜在的TB感染确实存在尽管如此,HAART无法恢复HIV / TB患者Mtb特异性IFN-γ应答所测量的最佳TB应答性,改善Mtb特异性免疫修复应成为研究的重点。未来的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号